

AMENDMENTS TO THE CLAIMS

1. – 38. (Canceled)

39. (Currently Amended) A method for treatment of tumors, which comprises administering to a subject in need thereof a composition comprising

(a) an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone; and

(b) ~~one or more~~ a tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide and a salt thereof ~~combretastatines, vinea alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphetiniles, flavonoids, rhizoxins, curacins A, epothilones A, epothilones B, welwistatins, phenstatins, 2-strylquinazoline 4(3H)-ones, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a) isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans, 2,3-substituted indoles, and 2-methoxyestradiol.~~

40. (Previously Presented) The method according to Claim 39, wherein said subject in need thereof is a human.

41. (Previously Presented) The method according to Claim 39, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

42. (Previously Presented) The method according to Claim 39, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

43. – 49. (Canceled)

50. (New) The method according to Claim 39, wherein (a) and (b) are administered simultaneously.

51. (New) The method according to Claim 39, wherein (a) and (b) are administered sequentially.

52. (New) The method according to Claim 39, wherein (a) is Dexamethasone.

53. (New) The method according to Claim 39, wherein (a) is an ester of Dexamethasone.

54. (New) The method according to Claim 39, wherein (a) is a salt of Dexamethasone.

55. (New) The method according to Claim 39, wherein (b) is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.

56. (New) The method according to Claim 39, wherein (b) is a salt of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.